Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
One single study has suggested that bone mineral density (BMD) is reduced in patients with
non-cirrhotic chronic viral hepatitis C. Antiviral combination therapy with standard
interferon and ribavirin may further decrease BMD. The aim of this study is to systematically
investigate the effect of chronic hepatitis C genotype 1 infection alone and current standard
therapy with peginterferon alfa-2a/ribavirin on BMD and bone metabolism.